Home / Products / Genome-edited Cells / FGD5-AS1 Knockout AC16 Cell Line

FGD5-AS1 Knockout AC16 Cell Line

Cat. No. ARG0116
Product Type:

Genome-edited Cells

Tissue Source:

Heart

In stock
Request a Quote

Short Description 🔒

FGD5-AS1 Knockout AC16 is a human CRISPR/Cas9-edited cardiomyocyte-like cell line with disruption of the lncRNA FGD5-AS1 in the AC16 ventricular cell background. AC16 cells are widely used to study cardiac stress signaling, apoptosis, hypertrophy, mitochondrial dysfunction, and injury-associated remodeling. FGD5-AS1 regulates ceRNA/miRNA networks and influences pathways involving PI3K-AKT, MAPK, TGF-beta, and Wnt/beta-catenin, with downstream effects on AKT1 phosphorylation, BCL2, BAX, and CASP3-associated responses. This model is useful for cardiac injury studies, oxidative stress research, fibrosis-associated signaling analysis, RNA interaction studies, and RT-qPCR, RNA-seq, phospho-signaling, apoptosis, and ROS-based assays.

Product Details
Cell Engineering
Immortalization
Culture Conditions
Quality Control
Disclaimer

Product Details

Product Type:
Genome-edited Cells
Tissue Source:
Heart
Disease:
Normal
Morphology:
Cardiomyocyte
Age:
Unknown
Sex of Donor:
Unknown
Size/Quantity:
1 million
Shipping info:
Cryopreserved in vials and shipped on dry ice

Cell Engineering Information

Host Cell:
AC16
Gene Name:
FGD5-AS1
Gene Identifier:
NCBI Gene ID 100505641
Gene Species:
Homo sapiens (Human)

Immortalization Information

No immortalization information available.

Culture Conditions

Temperature:
37°C
Atmosphere:
5% CO₂

Quality Control

Mycoplasma testing:
Negative for mycoplasma through PCR analysis
Sterility testing:
Daily monitoring confirms that the cells are free from bacterial, yeast, and fungal contamination.
Pathogens:
Cells tested negative for HIV-1, HBV, and HCV.

Disclaimer

Intended Use:
This product is intended for laboratory in vitro use only. It is not intended for diagnostic, therapeutic, or clinical applications.
Disclaimer:
Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability.
Usage:
By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use. This product is provided "AS IS".

Description 🔒

The FGD5-AS1 Knockout AC16 Cell Line is a human CRISPR/Cas9-engineered cell model in which the FGD5-AS1 locus has been disrupted to abolish functional expression of this long noncoding RNA. The resulting stable knockout line is generated in AC16 cells, an immortalized human cardiomyocyte-like background that supports mechanistic studies of cardiac gene regulation under basal and stress-induced conditions. This product provides an in vitro system for investigating how loss of FGD5-AS1 alters RNA-mediated regulatory networks and downstream signaling outputs relevant to cardiomyocyte injury, remodeling, and survival.

AC16 cells model ventricular cardiac muscle biology and are broadly used in studies of myocardial stress signaling, hypertrophy, apoptosis, mitochondrial dysfunction, and electrophysiology-associated responses. The line was derived from fusion of adult human ventricular cardiomyocytes with SV40-transformed fibroblasts, yielding a robust experimental platform that retains important features of cardiac cellular physiology while offering the practicality of an immortalized system. Because AC16 cells respond to oxidative stress, hypoxia, inflammatory stimulation, and injury-associated perturbations, they are widely applied in cardiovascular research addressing ischemia-reperfusion injury, heart failure, remodeling, and cardioprotective mechanisms.

FGD5-AS1 functions as a regulatory lncRNA within post-transcriptional gene control networks, predominantly through ceRNA-like interactions that alter microRNA availability. In this context, FGD5-AS1 is regulated by oxidative stress, hypoxia, inflammatory cytokines, TGF-beta, and broader cellular injury signals, and it interacts with microRNAs, AGO2-containing RISC complexes, RNA-binding proteins, and epigenetic regulatory complexes. Through these interactions, FGD5-AS1 can act upstream of signaling nodes including PI3K, AKT1, mTOR, MAPK1/3, TGFBR1, SMAD2/3, and CTNNB1, with downstream consequences for BCL2, BAX, CASP3, apoptosis-related genes, fibrosis-associated genes, proliferation programs, migration-associated gene expression, and oxidative stress response markers. These regulatory relationships make the lncRNA relevant to cardiovascular disease, myocardial fibrosis, vascular dysfunction, and broader stress-response biology.

Loss of FGD5-AS1 in AC16 cells is therefore a meaningful model for examining how lncRNA-dependent RNA interaction networks influence cardiomyocyte-like phenotypes. In this host-cell context, knockout may be used to interrogate injury-associated transcriptional reprogramming, pathway dependence of AKT phosphorylation, balance between pro-survival and pro-apoptotic signaling, and TGF-beta- or Wnt/beta-catenin-linked remodeling responses. The model is particularly suitable for defining how lncRNA depletion modifies stress sensitivity, apoptotic threshold, and fibrosis- or hypertrophy-associated molecular signatures in a human cardiac background.

This knockout cell line is well suited for RT-qPCR and RNA-seq analyses of lncRNA-regulated transcriptomic changes, as well as lncRNA expression profiling and ceRNA network studies focused on specific microRNA axes. Protein-level consequences can be assessed by western blotting or phospho-signaling analysis of AKT1, MAPK1/3, mTOR, SMAD2/3, CTNNB1, BCL2, BAX, and CASP3. Functional phenotyping can include apoptosis assays, caspase activity assays, flow cytometry, cell viability measurements, ROS quantification, mitochondrial membrane potential assays, and immunofluorescence following oxidative or hypoxic challenge. The model also supports migration assays, luciferase reporter assays for miRNA-responsive elements, and RNA immunoprecipitation to examine interactions with AGO2 or other RNA-binding factors. Researchers may contact Ascent Research for additional technical information, product details, or related gene-edited cell models.